Combining trastuzumab emtansine (T-DM1) and pertuzumab before surgery was more beneficial than the combination of paclitaxel plus trastuzumab for patients with HER2-positive invasive breast cancer.
Treatment with lapatinib and trastuzumab before surgery and chemotherapy led to significant shrinkage or disappearance of the tumors in approximately 25% of women with HER2-positive breast cancer.
Cyclin D1/CDK4 inhibitor treatment overcame resistance to targeted therapy in transgenic mouse models, cell cultures, and human tissue samples of HER2-positive breast cancer.
Women with the HER2-enriched type of HER2-positive breast cancer had the highest rate of immune response to treatment with trastuzumab, with a significant increase after just 1 dose of the drug.
A recent study examined genetic susceptibility in younger patients diagnosed with HER2+ breast cancer.
Researchers have discovered that ERBB4 (also known as HER4) is a driver protein in ERBB2-positive tumors that have developed resistance to first- or second-line treatments.
Women with stage 1 HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted drug following surgery were unlikely to suffer cancer recurrence within 3 years of treatment.
Patients with HER2-positive breast cancer that has metastasized demonstrate longer survival outcomes if treated with a combination of pertuzumab, trastuzumab, and chemotherapy.
The use of trastuzumab (Herceptin) as the standard-of-care treatment for HER2-positive breast cancer has been supported by the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) study.
Drug should remain standard of care for HER2-positive tumors, according to new research.
